立方制药：转让参股公司迈诺威2.2184%股权

Core Viewpoint - The company plans to recover investment costs by transferring a 2.2184% stake in Mainowei for a price of 22.183748 million yuan, while retaining a 4.28% stake post-transaction [1] Group 1 - The company has signed a share transfer agreement with Yuanhe Venture Capital for the stake transfer [1] - The registered capital corresponding to the stake being transferred is 116,614 yuan [1] - This transaction does not constitute a related party transaction or a major asset restructuring, and it will not change the scope of the company's consolidated financial statements [1]